DelveInsight’s “Acute On Chronic Liver Failure (ACLF) Pipeline Insight 2022” report provides comprehensive insights about key companies and pipeline drugs in the Acute On Chronic Liver Failure (ACLF) pipeline landscapes. 

The report comprises Acute On Chronic Liver Failure (ACLF) pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute On Chronic Liver Failure (ACLF) therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute On Chronic Liver Failure (ACLF) pipeline products.    

Some of the key takeaways from the Acute On Chronic Liver Failure (ACLF) Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Grifols Therapeutics, RHEACELL GmbH, Martin Pharmaceuticals, etc., are developing therapies for the treatment of Acute On Chronic Liver Failure (ACLF).

• Emerging therapies such as Carvedilol 12.5 MG, G-CSF, and Albumin, are expected to have a significant impact on the  Acute On Chronic Liver Failure (ACLF) market in the coming years. 

Acute On Chronic Liver Failure (ACLF) Overview

The term ‘acute-on-chronic liver failure (ACLF) defines an abrupt and life-threatening worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a serious condition with very high morbidity and mortality. According to European Association for the Study of the Liver – Chronic Liver Failure (EASL-CLIF) Consortium the definition of ACLF is based on the existence of the failure of 1 of the 6 major organ systems. The failure of each organ system is assessed using the CLIF-C Organ Failure scale.

According to NACSELD, the most prevalent organ system failures were brain (36%), followed by circulatory (16%), kidney (13%), and respiratory (9%).

Request a sample for the Pipeline Report: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight

Acute On Chronic Liver Failure (ACLF) Pipeline Therapies along with Key Players:

Pipeline Therapies:

• Carvedilol 12.5 MG

• Trimetazidine

• HepaStem

• G-CSF

• Albumin 

Key Companies:

• European Foundation for Chronic Liver Failure

• Grifols Therapeutics

• RHEACELL GmbH 

• Martin Pharmaceuticals

• Promethera Therapeutics

Scope of Acute On Chronic Liver Failure (ACLF) Pipeline Drug Insight    

• Coverage: Global 

• Major Players: Grifols Therapeutics, RHEACELL GmbH, Martin Pharmaceuticals, and others.

• Pipeline Therapies: Carvedilol 12.5 MG, G-CSF, Albumin, and others.

Table of Contents

Related Reports:

Acute On Chronic Liver Failure (ACLF) Market

DelveInsight’s ‘Acute On Chronic Liver Failure (ACLF)-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Acute On Chronic Liver Failure (ACLF) Epidemiology

DelveInsight’s ‘Acute On Chronic Liver Failure (ACLF) Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com